Drugs / Mirivadelgat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06475781 | Mar 2025 → Jun 2028 expected | pulmonary hypertension | Foresee Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Foresee Pharmaceuticals Co., Ltd. | Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial foreseepharma.com ↗ |
| 2025-05-14 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Announces First Patient Dosed in the Phase 2 WINDWARD Study of the ALDH2 Activator Mirivadelgat for Patients with Pulmonary Hypertension-Associated Interstitial Lung Disease (PH-ILD) foreseepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mirivadelgat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06475781 ↗ |
| Action | Activate | “Selective aldehyde dehydrogenase 2 (ALDH2) activator” NCT06475781 ↗ |
| Target | ALDH2 | “Selective aldehyde dehydrogenase 2 (ALDH2) activator” NCT06475781 ↗ |